CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. (HKSE: 1228) is trading at HK$1.85, about ₹23 at today's HKD/INR rate, as of 25 Sep 2026, 3:21 AM ET, down 1.07% today. Indian residents can buy CANbridge Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$1.85
Today's high
HK$1.90
52 week low
HK$1.61
52 week high
HK$3.50
1228 opened at HK$1.87, closed previously at HK$1.87, and has traded between HK$1.61 and HK$3.50 over the past 52 weeks.
About
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
Key statistics
Avg. volume
1.51M
Market cap
HK$785.95M
P/E Ratio
-10.02
Price-to-sales ratio
12.06
Enterprise value
CN¥612.22M
Free cash flow yield
-4.38%
Debt-to-equity ratio
-0.15
Return on equity
30.32%
ROIC
79.16%
Beta
-0.09
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥49.98M
Earnings per share
CN¥0.03
Free cash flow
-CN¥38.22M
Net profit margin
-146.41%
Gross margin
71.47%
EBITDA
-CN¥78.98M
Revenue growth
-41.27%
Similar securities
This is not an investment recommendation
How to buy CANbridge Pharmaceuticals from India
Indian residents can buy CANbridge Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for CANbridge Pharmaceuticals and place an order
Find CANbridge Pharmaceuticals by name or by its ticker, 1228, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. CANbridge Pharmaceuticals trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your CANbridge Pharmaceuticals position in HKD and INR. CANbridge Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in CANbridge Pharmaceuticals from India
Trading and taxes when buying CANbridge Pharmaceuticals from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneCANbridge Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy CANbridge Pharmaceuticals stock?
Yes. CANbridge Pharmaceuticals (1228) has been listed on the Hong Kong Stock Exchange since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one CANbridge Pharmaceuticals share cost in rupees?
One CANbridge Pharmaceuticals share is HK$1.85 — about ₹23 at an HKD/INR rate of 12.23 on 26 Sep 2026. Both the CANbridge Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying CANbridge Pharmaceuticals from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of CANbridge Pharmaceuticals?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on CANbridge Pharmaceuticals shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the CANbridge Pharmaceuticals price. Paasa issues a capital-gains statement for your return.
Does CANbridge Pharmaceuticals pay a dividend?
No. CANbridge Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade CANbridge Pharmaceuticals from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is CANbridge Pharmaceuticals a Hong Kong SAR China company, and does that change how it is taxed?
CANbridge Pharmaceuticals trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. CANbridge Pharmaceuticals trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare CANbridge Pharmaceuticals shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your CANbridge Pharmaceuticals holding, its cost and its closing value.
How do I sell CANbridge Pharmaceuticals and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.